Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Dirk Jan A R, Moes"'
Autor:
Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 612-623 (2024)
Abstract Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with non‐small cell lung cancer t
Externí odkaz:
https://doaj.org/article/ea749281c095497bbf69f8fe06f78a32
Autor:
Anna E. C. Stoelinga, Maarten E. Tushuizen, Wilbert B. van den Hout, Mar D. M. Rodriguez Girondo, Elsemieke S. de Vries, Amar D. Levens, Dirk-Jan A. R. Moes, Tom J. G. Gevers, Suzanne van der Meer, Hans T. Brouwer, Hendrik J. M. de Jonge, Ynte S. de Boer, Ulrich H. W. Beuers, Adriaan J. van der Meer, Aad P. van den Berg, Maureen M. J. Guichelaar, Joost P. H. Drenth, Bart van Hoek, on behalf of the Dutch Autoimmune Hepatitis Group
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immuno
Externí odkaz:
https://doaj.org/article/e9871b3711e44943a5adbb67b77352b2
Autor:
Aliede E. in ’t Veld, Boukje C. Eveleens Maarse, Maria J. Juachon, Soufian Meziyerh, Aiko P. J. deVries, Aline L. vanRijn, Mariet C. W. Feltkamp, Dirk Jan A. R. Moes, Jacobus Burggraaf, Matthijs Moerland
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 6, Pp n/a-n/a (2024)
Abstract The recommended immunosuppressive treatment after kidney transplantation consists of tacrolimus, mycophenolate mofetil, and low‐dose corticosteroids. Drug concentrations are monitored using therapeutic drug monitoring (TDM), which does not
Externí odkaz:
https://doaj.org/article/2c90a61949794a7c82425755b1b0fcc7
Autor:
Denise Feick, Simeon Rüdesheim, Fatima Zahra Marok, Dominik Selzer, Helena Leonie Hanae Loer, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1143-1156 (2023)
Abstract The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug–drug interaction (DDI) studies. However, as quinidine is also a subst
Externí odkaz:
https://doaj.org/article/503a323dba2b45ac83fda9c9d5d71582
Autor:
Qinglian Zhai, Dirk Jan A. R. Moes, Teun vanGelder, Maaike van derLee, Jan‐Stephan Sanders, Frederike J. Bemelman, Johan W. deFijter, Kathrin Klein, Matthias Schwab, Jesse J. Swen
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract CYP3A4 activity shows considerable interindividual variability. Although studies indicate 60%–80% is heritable, common single nucleotide variants (SNVs) in CYP3A4 together only explain ~10%. Transcriptional factors, such as the testis‐sp
Externí odkaz:
https://doaj.org/article/cf902441beee46b8b8ebb244b07235fe
Autor:
Helena Leonie Hanae Loer, Denise Feick, Simeon Rüdesheim, Dominik Selzer, Matthias Schwab, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Thorsten Lehr
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 5, Pp 724-738 (2023)
Abstract The immunosuppressant and narrow therapeutic index drug tacrolimus is metabolized mainly via cytochrome P450 (CYP) 3A4 and CYP3A5. For its pharmacokinetics (PK), high inter‐ and intra‐individual variability can be observed. Underlying ca
Externí odkaz:
https://doaj.org/article/8f442549019b44338f8e3c2b8a8de9ff
Autor:
Jasper Kamp, Tom C. Zwart, Soufian Meziyerh, Paul J. M. van der Boog, Esther E. Nijgh, Koen van Duin, Aiko P. J. de Vries, Dirk Jan A. R. Moes
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 17 (2023)
Background: Meltdose tacrolimus (Envarsus®) has been marketed as a formulation achieving a more consistent tacrolimus exposure. Due to the narrow therapeutic window of tacrolimus, dose individualization is essential. Relaxation of the upper age limi
Externí odkaz:
https://doaj.org/article/823bbd9525af48018c12a9c5f0e33213
Autor:
Stefanie D. Krens, Nielka P. van Erp, Stefanie L. Groenland, Dirk Jan A. R. Moes, Sasja F. Mulder, Ingrid M. E. Desar, Tom van der Hulle, Neeltje Steeghs, Carla M. L. van Herpen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Aim In the registration trial, cabozantinib exposure ≥ 750 ng/mL correlated to improved tumor size reduction, response rate and progression free survival (PFS) in patients with metastatic renal cell cancer (mRCC). Because patients in routi
Externí odkaz:
https://doaj.org/article/f27b5243be1f49888ffdb384331fa067
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Quantitative characterization of evolving tumor resistance under targeted treatment could help identify novel treatment schedules, which may improve the outcome of anti-cancer treatment. In this study, a mathematical model which considers va
Externí odkaz:
https://doaj.org/article/1ee39881ae464dc7bfd80c8292074cc0
Autor:
Aliede E. in ’t Veld, Manon A. A. Jansen, Marieke L. de Kam, Yalҫin Yavuz, Dirk Jan A. R. Moes, Kathalijne A. Oudhoff, Mariette I. E. van Poelgeest, Jacobus Burggraaf, Matthijs Moerland
Publikováno v:
Pharmaceutics, Vol 15, Iss 6, p 1635 (2023)
Mycophenolate mofetil (MMF) is part of the standard immunosuppressive treatment after transplantation and usually given as “one-dose-fits-all” together with a calcineurin inhibitor (CNI). Although drug concentrations are frequently monitored, the
Externí odkaz:
https://doaj.org/article/e24bae55d78c4c8da0807e221b2ee5e1